ACE-031 vs Carnosine

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

Dipeptide that buffers lactic acid in muscle during high-intensity exercise; chelates metal ions; prevents and reverses protein glycation; scavenges aldehyde oxidative byproducts

Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) synthesized in skeletal muscle and other excitable tissues from β-alanine and histidine, where it functions as an intracellular pH buffer, antioxidant, and antiglycation agent that supports cellular homeostasis under metabolic stress. Its principal role in exercise physiology centers on buffering the proton accumulation associated with high-intensity anaerobic work, attenuating acidosis-driven impairment of contractile function and extending time to fatigue during supra-threshold effort. Human randomized controlled trials using β-alanine supplementation — which elevates muscle carnosine content by increasing substrate availability — have demonstrated attenuation of fatigue during repeated high-intensity exercise bouts in trained athletes, providing the primary human evidence base for carnosine's performance effects. Carnosine is available as an oral dietary supplement in many jurisdictions; the evidence base for muscle carnosine loading via oral β-alanine supplementation is established in human RCTs, while direct exogenous carnosine administration by injection remains investigational with no regulatory approval or established clinical evidence base.